CFD merupakan instrumen yang rumit dan memiliki risiko tinggi kehilangan uang secara cepat karena adanya pengaruh leverage. 84% akun investor ritel mengalami kerugian saat melakukan kegiatan perdagangan CFD dengan penyedia ini. Anda harus mempertimbangkan apakah Anda memahami cara kerja CFD dan apakah Anda mampu menerima risiko tinggi kehilangan uang.
Country • United States
    Entity • country not supported, please select another country
    English العَرَبِيَّة Bahasa Indonesia Български Čeština Dansk Deutsch Eesti ελληνικά Español Français Hrvatski Italiano Latviešu Lietuvių Magyar Nederlands Polski Português Română Русский Slovenčina Slovenščina Suomi Svenska Tiếng Việt ไทย 简体中文 繁體中文

    Perdagangan CytomX Therapeutics Inc - CTMX CFD

    1.86
    0%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.05
    Biaya inap posisi Long

    Long position overnight fee

    Margin. Your investment $1,000.00
    Biaya Overnight -0.024874 %
    Charges from borrowed part ($-0.99)
    Trade size with leverage ~ $5,000.00
    Money from leverage ~ $4,000.00
    Kunjungi platform
    		-0.024874%
    Biaya inap posisi short

    Short position overnight fee

    Margin. Your investment $1,000.00
    Biaya Overnight 0.002651 %
    Charges from borrowed part ($0.11)
    Trade size with leverage ~ $5,000.00
    Money from leverage ~ $4,000.00
    Kunjungi platform
    		0.002651%
    Waktu biaya inap 21:00 (UTC)
    Kuantitas min. yang diperdagangkan 1
    Mata uang USD
    Margin 20%
    Bursa efek United States of America
    Komisi perdagangan 0%

    *Information provided by Capital.com

    Key Stats
    Prev. Close* 1.85
    Open* 1.78
    1-Year Change* -3.78%
    Day's Range* 1.78 - 1.95
    52 wk Range 1.17-3.02
    Average Volume (10 days) 1.30M
    Average Volume (3 months) 55.30M
    Market Cap 100.00M
    P/E Ratio -100.00K
    Shares Outstanding 66.23M
    Revenue 53.16M
    EPS -1.51
    Dividend (Yield %) N/A
    Beta 0.65
    Next Earnings Date May 3, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Jun 29, 2022 1.86 0.04 2.20% 1.82 1.96 1.78
    Jun 28, 2022 1.85 -0.09 -4.64% 1.94 1.94 1.80
    Jun 27, 2022 1.92 0.04 2.13% 1.88 1.97 1.83
    Jun 24, 2022 1.87 -0.05 -2.60% 1.92 1.97 1.83
    Jun 23, 2022 1.84 0.14 8.24% 1.70 1.85 1.70
    Jun 22, 2022 1.77 0.12 7.27% 1.65 1.81 1.62
    Jun 21, 2022 1.68 0.06 3.70% 1.62 1.71 1.58
    Jun 17, 2022 1.58 -0.03 -1.86% 1.61 1.70 1.57
    Jun 16, 2022 1.63 -0.04 -2.40% 1.67 1.67 1.57
    Jun 15, 2022 1.70 0.07 4.29% 1.63 1.73 1.61
    Jun 14, 2022 1.65 -0.05 -2.94% 1.70 1.72 1.64
    Jun 13, 2022 1.71 -0.03 -1.72% 1.74 1.76 1.68
    Jun 10, 2022 1.83 -0.02 -1.08% 1.85 1.85 1.77
    Jun 9, 2022 1.92 0.07 3.78% 1.85 1.93 1.81
    Jun 8, 2022 1.88 0.02 1.08% 1.86 1.98 1.86
    Jun 7, 2022 1.86 0.16 9.41% 1.70 1.91 1.67
    Jun 6, 2022 1.71 -0.06 -3.39% 1.77 1.83 1.71
    Jun 3, 2022 1.76 0.22 14.29% 1.54 1.78 1.54
    Jun 2, 2022 1.58 0.06 3.95% 1.52 1.59 1.49
    Jun 1, 2022 1.53 -0.05 -3.16% 1.58 1.67 1.50

    CytomX Therapeutics Inc Events

    Time (UTC) Country Event
    No events scheduled
    View all events
    • Annual
    • Quarterly
    2021 2020 2019 2018 2017
    Total revenue 69.573 100.362 57.489 59.502 71.623
    Revenue 69.573 100.362 57.489 59.502 71.623
    Total Operating Expense 153.354 148.967 168.384 137.376 117.882
    Selling/General/Admin. Expenses, Total 39.16 36.031 36.765 33.51 25.605
    Research & Development 114.194 112.936 131.619 103.866 92.277
    Operating Income -83.781 -48.605 -110.895 -77.874 -46.259
    Interest Income (Expense), Net Non-Operating 0.255 1.836 8.365 7.641 2.674
    Other, Net -0.083 -0.027 -0.135 -0.068 -0.027
    Net Income Before Taxes -83.609 -46.796 -102.665 -70.301 -43.612
    Net Income After Taxes -83.609 -32.885 -102.238 -84.604 -68.799
    Net Income Before Extra. Items -83.609 -32.885 -102.238 -84.604 -68.799
    Net Income -83.609 -32.885 -102.238 -84.604 -43.099
    Total Adjustments to Net Income 0
    Income Available to Common Excl. Extra. Items -83.609 -32.885 -102.238 -84.604 -68.799
    Income Available to Common Incl. Extra. Items -83.609 -32.885 -102.238 -84.604 -43.099
    Diluted Net Income -83.609 -32.885 -102.238 -84.604 -43.099
    Diluted Weighted Average Shares 64.1469 46.1456 45.3359 41.6644 37.1668
    Diluted EPS Excluding Extraordinary Items -1.3034 -0.71264 -2.25512 -2.03061 -1.85109
    Dividends per Share - Common Stock Primary Issue 0 0
    Diluted Normalized EPS -1.3034 -0.71264 -2.25512 -2.03061 -1.85109
    Total Extraordinary Items 25.7
    Sep 2022 Jun 2022 Mar 2022 Dec 2021 Sep 2021
    Total revenue 16.915 18.165 17.136 19.727 17.587
    Revenue 16.915 18.165 17.136 19.727 17.587
    Total Operating Expense 40.857 42.907 41.102 46.035 40.228
    Selling/General/Admin. Expenses, Total 10.49 11.748 10.543 9.456 11.085
    Research & Development 30.367 31.159 30.559 36.579 29.143
    Operating Income -23.942 -24.742 -23.966 -26.308 -22.641
    Interest Income (Expense), Net Non-Operating 0.616 0.262 0.068 0.073 0.07
    Other, Net 0.03 0.296 0.013 0.007 -0.013
    Net Income Before Taxes -23.296 -24.184 -23.885 -26.228 -22.584
    Net Income After Taxes -23.296 -24.184 -23.885 -26.228 -22.584
    Net Income Before Extra. Items -23.296 -24.184 -23.885 -26.228 -22.584
    Net Income -23.296 -24.184 -23.885 -26.228 -22.584
    Income Available to Common Excl. Extra. Items -23.296 -24.184 -23.885 -26.228 -22.584
    Income Available to Common Incl. Extra. Items -23.296 -24.184 -23.885 -26.228 -22.584
    Diluted Net Income -23.296 -24.184 -23.885 -26.228 -22.584
    Diluted Weighted Average Shares 65.9123 65.5428 65.3937 65.3086 65.2081
    Diluted EPS Excluding Extraordinary Items -0.35344 -0.36898 -0.36525 -0.4016 -0.34634
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.3231 -0.36898 -0.36525 -0.4016 -0.34634
    • Annual
    • Quarterly
    2021 2020 2019 2018 2017
    Total Current Assets 310.301 324.013 303.335 445.475 388.601
    Cash and Short Term Investments 305.226 316.119 296.145 436.127 374.11
    Cash & Equivalents 205.53 191.859 188.425 247.577 177.548
    Short Term Investments 99.696 124.26 107.72 188.55 196.562
    Total Receivables, Net 0.79 0.798 0.013 0.097 10.139
    Accounts Receivable - Trade, Net 0.79 0.798 0.013 0.097 10.139
    Prepaid Expenses 4.285 7.096 7.177 9.251 4.352
    Total Assets 339.411 358.663 341.282 457.108 397.644
    Property/Plant/Equipment, Total - Net 25.322 29.445 32.754 6.934 4.218
    Property/Plant/Equipment, Total - Gross 39.154 40.871 41.804 13.88 9.426
    Accumulated Depreciation, Total -13.832 -11.426 -9.05 -6.946 -5.208
    Goodwill, Net 0.949 0.949 0.949 0.949 0.949
    Intangibles, Net 1.021 1.167 1.312 1.458 1.604
    Other Long Term Assets, Total 1.818 3.089 2.932 2.292 2.272
    Total Current Liabilities 106.316 100.924 85.59 97.908 61.147
    Accounts Payable 2.818 2.996 4.158 5.132 4.205
    Accrued Expenses 34.236 23.059 30.051 26.724 16.383
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 69.262 74.869 51.381 66.052 40.559
    Total Liabilities 250.032 308.86 290.169 326.225 327.748
    Total Long Term Debt 0 0 0 0 0
    Deferred Income Tax
    Other Liabilities, Total 143.716 207.936 204.579 228.317 266.601
    Total Equity 89.379 49.803 51.113 130.883 69.896
    Common Stock 0.001 0.001 0.001 0.001 0.001
    Additional Paid-In Capital 623.344 499.964 468.285 445.956 289.454
    Retained Earnings (Accumulated Deficit) -533.724 -450.115 -417.23 -314.981 -219.465
    Other Equity, Total -0.242 -0.047 0.057 -0.093 -0.094
    Total Liabilities & Shareholders’ Equity 339.411 358.663 341.282 457.108 397.644
    Total Common Shares Outstanding 65.3928 48.2518 45.5231 45.0832 38.4786
    Preferred Stock - Non Redeemable, Net 0 0 0
    Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
    Total Current Assets 268.444 310.301 240.998 271.005 400.008
    Cash and Short Term Investments 262.53 305.226 236.289 266.177 393.796
    Cash & Equivalents 163.488 205.53 236.284 256.146 329.666
    Short Term Investments 99.042 99.696 0.005 10.031 64.13
    Total Receivables, Net 1.016 0.79 0.887 0.931 0.756
    Accounts Receivable - Trade, Net 1.016 0.79 0.887 0.931 0.756
    Prepaid Expenses 4.898 4.285 3.822 3.897 5.456
    Total Assets 296.825 339.411 371.233 402.44 434.158
    Property/Plant/Equipment, Total - Net 24.629 25.322 26.441 27.66 28.908
    Goodwill, Net 0.949 0.949 0.949 0.949 0.949
    Intangibles, Net 0.984 1.021 1.057 1.094 1.13
    Other Long Term Assets, Total 1.819 1.818 1.819 1.818 3.163
    Total Current Liabilities 102.766 106.316 99.772 93.377 98.049
    Accounts Payable 1.721 2.818 1.516 1.755 2.582
    Accrued Expenses 31.032 34.236 25.167 19.253 18.831
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 70.013 69.262 73.089 72.369 76.636
    Total Liabilities 228.631 250.032 259.559 271.487 288.136
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 125.865 143.716 159.787 178.11 190.087
    Total Equity 68.194 89.379 111.674 130.953 146.022
    Preferred Stock - Non Redeemable, Net 0 0
    Common Stock 0.001 0.001 0.001 0.001 0.001
    Additional Paid-In Capital 626.721 623.344 619.117 615.849 611.733
    Retained Earnings (Accumulated Deficit) -557.609 -533.724 -507.496 -484.912 -465.669
    Other Equity, Total -0.919 -0.242 0.052 0.015 -0.043
    Total Liabilities & Shareholders’ Equity 296.825 339.411 371.233 402.44 434.158
    Total Common Shares Outstanding 65.3984 65.3928 65.2491 65.157 65.0029
    Long Term Investments 99.969 99.914
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -99.317 -115.87 -32.885 -102.238 -84.604
    Cash From Operating Activities -110.788 -119.031 5.259 -140.48 -75.521
    Cash From Operating Activities 2.297 2.56 2.427 2.459 1.884
    Deferred Taxes
    Non-Cash Items 16.74 16.572 17.437 18.474 15.177
    Changes in Working Capital -30.654 -22.439 18.134 -59.321 -7.978
    Cash From Investing Activities 98.26 22.489 -18.718 79.701 5.926
    Capital Expenditures -1.74 -1.609 -2.309 -3.497 -3.788
    Other Investing Cash Flow Items, Total 100 24.098 -16.409 83.198 9.714
    Cash From Financing Activities 0.648 110.213 16.893 1.627 139.624
    Financing Cash Flow Items 0.648 0
    Issuance (Retirement) of Stock, Net 110.213 16.893 1.627 139.624
    Issuance (Retirement) of Debt, Net
    Net Change in Cash -11.88 13.671 3.434 -59.152 70.029
    Amortization 0.146 0.146 0.146 0.146
    Cash Taxes Paid 0 0 13.061
    Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021
    Net income/Starting Line -99.317 -71.365 -48.069 -23.885 -115.87
    Cash From Operating Activities -110.788 -109.394 -75.55 -41.313 -119.031
    Cash From Operating Activities 2.297 1.725 1.139 0.565 2.56
    Amortization 0.146 0.11 0.073 0.037 0.146
    Non-Cash Items 16.74 13.04 9.497 4.179 16.572
    Changes in Working Capital -30.654 -52.904 -38.19 -22.209 -22.439
    Cash From Investing Activities 98.26 -1.558 -1.148 -0.736 22.489
    Capital Expenditures -1.74 -1.558 -1.148 -0.736 -1.609
    Other Investing Cash Flow Items, Total 100 0 0 0 24.098
    Cash From Financing Activities 0.648 0.458 0.458 0.007 110.213
    Issuance (Retirement) of Stock, Net 0.458 0.458 0.007 110.213
    Net Change in Cash -11.88 -110.494 -76.24 -42.042 13.671
    Financing Cash Flow Items 0.648
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    BVF Partners L.P. Hedge Fund 9.9809 6595801 0 2022-12-31 LOW
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 6.9392 4585721 47760 2022-12-31 LOW
    Tang Capital Management, LLC Hedge Fund 5.3121 3510445 10445 2022-12-31 MED
    Acadian Asset Management LLC Investment Advisor/Hedge Fund 4.0154 2653576 0 2022-12-31 MED
    Rubric Capital Management LP Hedge Fund 3.6415 2406449 0 2022-12-31 MED
    Millennium Management LLC Hedge Fund 2.6024 1719811 1187298 2022-12-31 HIGH
    Medical Strategy GmbH Investment Advisor 2.5583 1690646 0 2022-09-30 LOW
    Renaissance Technologies LLC Hedge Fund 2.0289 1340774 -464826 2022-12-31 HIGH
    Two Sigma Investments, LP Hedge Fund 1.9581 1293989 408628 2022-12-31 HIGH
    BlackRock Institutional Trust Company, N.A. Investment Advisor 1.9432 1284168 -468950 2022-12-31 LOW
    Laurion Capital Management LP Hedge Fund 1.9231 1270900 0 2022-12-31 HIGH
    Assenagon Asset Management S.A. Investment Advisor 1.3844 914900 -150492 2022-12-31 HIGH
    Fidelity Management & Research Company LLC Investment Advisor 1.0582 699283 15074 2022-12-31 LOW
    Jacobs Levy Equity Management, Inc. Investment Advisor/Hedge Fund 1.045 690609 -438449 2022-12-31 MED
    Platinum Asset Management Investment Advisor/Hedge Fund 0.9621 635798 -593747 2022-12-31 LOW
    D. E. Shaw & Co., L.P. Hedge Fund 0.9357 618374 128744 2022-12-31 MED
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.9126 603075 15624 2022-12-31 LOW
    Newtyn Management, LLC Hedge Fund 0.8625 570000 -230000 2022-12-31 MED
    Oasis Management Company Ltd. Investment Advisor/Hedge Fund 0.818 540541 0 2022-12-31 LOW
    Gluck (Frederick W) Individual Investor 0.8021 530069 0 2022-04-18 LOW

    Mengapa memilih Capital.com? Biarlah angka kami yang berbicara.

    Capital.com Group

    500K+

    Trader

    92K+

    Klien aktif per bulan

    $53M+

    Volume investasi per bulan

    $30M+

    Penarikan tiap bulan

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results
    Laba/Loss
    Industry: Bio Therapeutic Drugs

    650 Gateway Blvd.
    Suite 125
    94080

    Income Statement

    • Annual
    • Quarterly

    People also watch

    Natural Gas

    2.20 Price
    +3.540% 1D Chg, %
    Biaya inap posisi Long -0.4092%
    Biaya inap posisi short 0.3873%
    Waktu biaya inap 21:00 (UTC)
    Spread 0.005

    Gold

    1,969.66 Price
    -0.550% 1D Chg, %
    Biaya inap posisi Long -0.0185%
    Biaya inap posisi short 0.0102%
    Waktu biaya inap 21:00 (UTC)
    Spread 0.30

    BTC/USD

    28,489.75 Price
    +0.050% 1D Chg, %
    Biaya inap posisi Long -0.0616%
    Biaya inap posisi short 0.0137%
    Waktu biaya inap 21:00 (UTC)
    Spread 60.00

    Oil - Crude

    75.76 Price
    +1.830% 1D Chg, %
    Biaya inap posisi Long -0.0156%
    Biaya inap posisi short -0.0063%
    Waktu biaya inap 21:00 (UTC)
    Spread 0.03

    Masih mencari broker yang bisa Anda percayai?

    Bergabung dengan 500.000+ trader di seluruh dunia yang telah memilih trading bersama Capital.com

    1. Buat & verifikasi akun Anda 2. Lakukan deposit 3. Temukan trading Anda